Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 7,631 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Heart Failure
Interventions: Baxdrostat and dapagliflozin, Placebo and dapagliflozin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 11,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 217
States / cities: Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more

Conditions: Lung Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more

Conditions: HIV Infections
Interventions: Nevirapine, Lamivudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 13 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 53
States / cities: Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more

Conditions: Degenerative Disc Disease, Spondylolisthesis
Interventions: Not listed
Lead sponsor: NuVasive; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 15
States / cities: Hartford, Connecticut • Jacksonville, Florida • Tampa, Florida + 12 more

Conditions: Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation
Interventions: Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 30
States / cities: Anchorage, Alaska • Phoenix, Arizona • Santa Monica, California + 27 more

Conditions: Cerebrovascular Disease, Ischemic Stroke, Transient Ischemic Attack, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage, Vascular Dementia, Anoxic Brain Injury, Unruptured Intracranial Aneurysm, Carotid Artery Stenosis Symptomatic, Asymptomatic Carotid Artery Stenosis, Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage, Cerebral Venous Thrombosis, Moyamoya Disease, Fibromuscular Dysplasia, Subarachnoid Hemorrhage, Leukoaraiosis, Arteriovenous Fistula, Reversible Cerebral Vasoconstriction Syndrome, CADASIL
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Renal Cell Carcinoma
Interventions: Opdivo, Yervoy; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Jacksonville, Florida • Iowa City, Iowa • Charlotte, North Carolina + 1 more

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Golimumab 50 mg, Golimumab 100 mg; Drug · Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more

Conditions: Blood Loss, Surgical
Interventions: Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel); Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: Not listed
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 25 Years
Enrollment: 723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 29 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1023
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more

Conditions: Rhegmatogenous Retinal Detachment - Macula Off
Interventions: ONL1204 Ophthalmic Solution, Sham treatment; Drug
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more

Conditions: Degenerative Disc Disease, Degenerative Spondylolisthesis
Interventions: SpineLink® , SpineLink® II; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: Not listed
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 2
States / cities: San Diego, California • Jacksonville, Florida

Conditions: Pancreatic Cancer
Interventions: MORAb-009, Placebo, Gemcitabine; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: La Jolla, California • San Diego, California • Vallejo, California + 22 more

Conditions: Asthma
Interventions: FP 100mcg, FSC 100/50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 141
States / cities: Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more

Conditions: Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions: AMG 397, Dexamethasone, Azacitidine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more

Conditions: Heart Failure, Congestive
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more

Conditions: Celiac Disease
Interventions: VTP-1000, Matched Placebo; Biological · Other
Lead sponsor: Barinthus Biotherapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • Colorado Springs, Colorado • Jacksonville, Florida + 13 more

Conditions: Non-Small-Cell Lung Carcinoma NSCLC
Interventions: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 35
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more

Conditions: Glioma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Postmenopausal Osteoporosis
Interventions: teriparatide, aldrenodate, raloxifene; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more

Conditions: Scleroderma, Systemic
Interventions: Avenciguat (BI 685509), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Search by objective public record fields.

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

Advanced Materials Science in XLIF Study

Clinical Investigation of the Medtronic Concerto™ Device

Florida Cerebrovascular Disease Biorepository and Genomics Center

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Advair Pediatric Once-Daily

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

VTP-1000 in Adults With Celiac Disease

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Advanced Development of Desorption Electrospray Ionization Mass Spectrometry for Intraoperative Molecular Diagnosis of Brain Cancer Using Pathology Biopsies

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN